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Reversibly switchable proteins are powerful tools with which to explore protein function in vitro and in vivo. For example, the
activity of many proteins fused to the hormone-binding domain of the modiﬁed oestrogen receptor (ERTAM) can be regulated by
provision or removal of 4-hydroxytamoxifen (4-OHT). Despite the widespread use of ERTAM fusions in vivo, inadequate data are
available as to the most efﬁcacious routes for systemic tamoxifen delivery. In this study, we have used two well-characterized ERTAM
fusion proteins, both reversibly activated by 4-OHT, to compare the effectiveness and kinetics of 4-OHT delivery in mice in vivo by
either tamoxifen in food or by intraperitoneal injection. Our data indicate that dietary tamoxifen offers an effective, facile and
ethically preferable means for long-term activation of ERTAM fusion proteins in vivo.
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INTRODUCTION
In classical mouse genetics, the function of a speciﬁc gene is
irreversibly mutated or deleted in the germ-line and the
phenotype that manifests is an amalgam of both, the direct
consequences of the mutation together with the extent to which
those direct consequences drive compensatory adaptation during
development. Such developmental compensation, together with
the embryonic lethality associated with other mutations, severely
limits the information that such ‘germ-line’ genetics can provide
on the roles played by genes in adult tissues. The inability to
reverse the germ-line alterations of genes in classical genetics
further limits determination of adult gene function. Such
considerations have fostered the idea of using reversibly switch-
able genetic technologies, whereby wild-type gene functions may
be reversibly toggled on and off, at will, in adult mice, either
systemically or tissue by tissue.
When fused to a heterologous protein, the modiﬁed oestrogen
receptor ligand-binding domain (ERTAM) may be used to render
that protein rapidly and reversibly ectopically regulatable by the
ERTAM ligand 4-hydroxytamoxifen (4-OHT), see http://www.picard.
ch/downloads for annotated list of proteins that have successfully
been regulated by fusion with a steroid-binding domain. Most
notably, ERTAM fusions with various oncoproteins and tumour
suppressor proteins have been successfully employed in trans-
genic and knock-in mouse cancer models to ascertain the roles of
such effectors in both tumour initiation and maintenance.1–4
However, the efﬁciency of tamoxifen delivery and activation
of ERTAM fusion proteins has hitherto only been assessed for
‘hit-and-run’ activation functions, such as activation of Cre-ERTAM
by determining the extent of recombination of speciﬁc ﬂoxed
alleles.8–10 However, such acute studies offer little guidance as to
the practical utility of tamoxifen administration in sustaining the
activities of ERTAM fusion proteins over protracted periods in vivo,
as is required for modelling chronic pathologies such as cancer
that typically requires long-term administration of ERTAM ligand to
sustain activities of oncogenic ERTAM fusion proteins. For such
purposes, 4-OHT is prohibitively expensive and, consequently,
most in vivo studies instead use tamoxifen, which is cheaper and is
readily metabolized by the liver into the active 4-OHT metabolite
by the cytochrome P450 CYP2D6 and CYP3A4 isoforms.5
Unfortunately, tamoxifen has a relatively short half-life in vivo
(about 16 h)6 and is poorly soluble in aqueous preparations so, to
date, the most consistent results for sustained activation of ERTAM
fusion proteins have been obtained through daily intraperitoneal
injection (i.p.) of tamoxifen dispersed in vegetable oil.7 However,
administration via this route is both labour-intensive and ethically
debatable because it can result in sterile peritonitis due to the
accumulation of oil. Indeed, six weeks of daily injections is the
maximum that can be realistically tolerated, therefore, extended
treatment with tamoxifen is usually impractical. Despite the
widespread use of ERTAM fusions in vivo, scant data are available
on the most efﬁcacious routes for long-term tamoxifen delivery.
We therefore sought to ascertain the kinetics of tamoxifen-
induced activation of ERTAM-fusion proteins in response to various
routes of tamoxifen administration and to investigate more
sustainable tamoxifen delivery methods for long-term analysis.
RESULTS AND DISCUSSION
We employed two well-characterized mouse models whose
biologies are dependent upon activities of ERTAM fusion proteins.
First, the pIns-MycERTAM mouse, in which transgenic overexpres-
sion of the 4-OHT-dependent allele of the c-Myc oncoprotein,
MycERTAM, is driven from the rat insulin promoter in pancreatic
β-cells. Administration of tamoxifen to such animals activates
oncogenic Myc, triggering widespread Myc-induced β-cell apop-
tosis and islet involution. However, co-expression of the anti-
apoptotic protein Bcl-xL in β-cells blocks Myc-induced apoptosis,
whereupon Myc activation drives and maintains synchronous,
rapid, persistent and progressive β-cell expansion accompanied
by angiogenesis, inﬂammation, invasion and tumorigenesis.11
Subsequent de-activation of MycERTAM triggers complete regres-
sion of the β-cell tumours. Second, we used Trp53tm1Gev mice
(hereafter called p53KI/KI), in which both copies of endogenous p53
are replaced by a gene encoding the 4-OHT-dependent p53 allele
p53ERTAM.4 In these animals, p53 function is continuously
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dependent upon the provision of 4-OHT ligand. Hence, in the
absence of tamoxifen, p53KI/KI mice are effectively p53 null and
radiosensitive tissues, such as thymus, spleen and intestinal
epithelium, exhibit signiﬁcant refractoriness to radiation-induced
apoptosis, as they do in p53− /− mice. However, p53-dependent
radiosensitivity of p53KI/KI tissues is rapidly restored upon systemic
administration of tamoxifen.4
To assess whether dietary tamoxifen is a feasible means for
regulating ERTAM protein activity in vivo, we ﬁrst assessed the
dynamics of oncogenic MycERTAM activation in pIns-MycERTAM;
RIP7-Bcl-xL mice (also known as Tg(Ins-BCL2L1)2Ksp;Tg(Ins-MYC/Er)
1Gev mice).11 Myc-driven pancreatic insulinomas were induced in
8- to 15-week-old pIns-MycERTAM;RIP7-Bcl-xL (n⩾ 3) mice by either
daily i.p. of 0.8 mg tamoxifen in oil or dietary tamoxifen for 7 days.
β-cell proliferation in pancreata was then assessed by immuno-
histochemical staining for the proliferative marker Ki67. Control
RIP7-Bcl-xL mice exhibited little β-cell proliferation (o0.4 Ki67
positive cells per unit area) irrespective of tamoxifen delivery or
route of administration. By contrast, administration of tamoxifen
to pIns-MycERTAM;RIP7-Bcl-xL mice, by either injection or diet,
elicited similarly dramatic levels of β-cell proliferation (P= 0.85,
Figure 1), indicating that MycERTAM-activating doses of tamoxifen
are achievable by both administration methods. Hence, adminis-
tration of tamoxifen through diet is an effective means for
achieving ERTAM-activating levels of 4-OHT in tissues in vivo.
To establish the kinetics and persistence of tamoxifen-
dependent activation of ERTAM proteins in tissues in vivo, we used
the p53KI/KI mouse model, assessing 4-OHT-dependent p53
functionality using responses of radiosensitive tissues to patho-
logical doses of γ-irradiation. Tamoxifen was administered to
8–12-week-old homozygous p53KI/KI mice (and to p53+/+ and
p53− /− controls) by either (i) single intraperitoneal bolus of 1 mg
tamoxifen dissolved in oil or by feeding mice with tamoxifen-
impregnated food for (ii) 24 h or (iii) 7 days. Mice were then
exposed to 2.5 Gy whole body γ-irradiation (Cs source) at various
times after bolus tamoxifen administration or after removal from
tamoxifenized food, and the thymus and spleen were collected 4
h later. p53 functionality was assessed by quantifying apoptosis in
the thymus (immunohistochemical staining for cleaved caspase-3)
(Figures 2a–c) and by assaying levels of p21cip1 expression in the
spleen (Supplementary Figure 1).
As expected, untreated p53+/+ control mice exhibited high
levels of both apoptosis and p21cip1 expression following
irradiation whereas non-tamoxifen-treated p53KI/KI mice (as well
as p53− /− controls), exhibited little (Supplementary Figure 2).
Signiﬁcant apoptosis and p21cip1 expression were evident in the
radiosensitive tissues of p53KI/KI within only 2 h of i.p. administra-
tion of 1 mg tamoxifen, peaking around 4 h post injection and
then falling back to background levels between 24–48 h post
treatment. Hence, tamoxifen adminstered i.p. rapidly and systemi-
cally restores functionality to p53ERTAM tissues in vivo. Attenuation
of radiosensitivity was more rapid (50% reduction in p21cip1
expression by 8 h post irradiation) in mice given a single i.p.
injection of a reduced (0.8 mg) tamoxifen dose (estimated to be
equivalent to the dose received via chow, see below) whereas a
higher dose (4 mg) elicited a more sustained p53ERTAM function-
ality (more than 80% of peak p21cip1 expression was maintained to
8 h post irradiation). However, higher doses of tamoxifen did not
increase the extent of p21cip1 activation at 2 h post irradiation
(Supplementary Figure 3A), indicating that the level of p53
activation is directly dependent on tamoxifen availability and that
tamoxifen doses via i.p. greater than 0.8 mg tamoxifen are fully
saturating for p53ERTAM in vivo and that higher doses merely
confer more prolonged ERTAM fusion protein activity.
We next investigated the kinetics of ERTAM activation when
delivering tamoxifen through food. p53KI/KI mice exposed to
tamoxifen-containing food for 24 h exhibited no measurable
increase in radiosensitivity. This is most likely due to the fact that
over the ﬁrst 24-h period, mice only ate on average 2.3 g of
tamoxifen-containing food (n= 14, range 1–3 g), which is around
half of their normal daily intake and, consequently, exhibited on
average 8.5% weight loss (n= 14, range 0–19%). We guess that the
level of tamoxifen in the animals is insufﬁcient to activate
p53ERTAM and, for this reason, dietary tamoxifen is unsuitable
for studies requiring acute activation of ERTAM proteins. However,
tissues of p53KI/KI mice exposed to tamoxifen-containing food for
7 days was sufﬁcient to render tissues fully radiosensitive, as
evidenced by extensive radiation-induced apoptosis and p21cip1
expression that then fell to background levels by 16–24 h of
surcease of dietary tamoxifen (Figure 2 and Supplementary
Figure 1C). The actual DNA damage induced by γ-irradiation, as
assessed by phospho-Histone H2A.X staining, was comparable in
Figure 1. Persistence of c-Myc functionality in pIns-MycERTAM;RIP7-Bcl-xL mice after different routes of tamoxifen administration
(a) Representative images of pancreatic islets stained for the Ki67 proliferative marker from pIns-MycERTAM;RIP7-Bcl-xL and RIP7-Bcl-xL controls
showing enlarged highly proliferative hyperplastic islets. The histogram depicts quantiﬁcation of Ki67 immunohistochemical staining.
Quantiﬁcation was performed on three islets per mouse and area measured; Ki67 positive stained cells were counted per islet and ratio per
unit area was calculated. No signiﬁcant difference was calculated (t-test, P= 0.85) between pIns-MycERTAM;RIP7-Bcl-xL mice treated with either
injection or dietary tamoxifen. Mean and s.e.m. shown, ***Po0.001, **Po0.01. Primary antibody: anti-Ki67 (Thermo Scientiﬁc, Fremont, CA,
USA; clone: SP6; 1:200).
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all tissues irrespective of tamoxifen provision (Supplementary
Figure 3B).
To examine directly the rate of metabolism/excretion of
tamoxifen in each experimental system, we determined the level
of 4-OHT, the ERTAM-activating tamoxifen metabolite, in the blood
plasma of pure C57BL6J mice (Supplementary Figure 4) using
LC/MS (liquid chromatography–mass spectrometry). These studies
conﬁrmed that plasma 4-OHT is evident 2 h post single i.p.
administration of 0.8 mg tamoxifen, returning to background
levels after 24–48 h. Sustained dietary administration of
tamoxifen-containing food for 7 days resulted in signiﬁcant
plasma 4-OHT and this fell to undetectable levels between 8
and 24 h after surcease of dietary tamoxifen. Thus 4-OHT, once
tamoxifen has been ingested or injected, is cleared from tissues
within 24 h, attesting to the need for repeated daily administration
of tamoxifen in situations to maintain ERTAM fusion protein
function. Once animals have become acclimatized to dietary
tamoxifen for at least 7 days they receive on average a 0.8 mg
daily dose of tamoxifen over a 24-h period from grazing on food.
This is reﬂected in the observation that 4-OHT levels and
corresponding functional readout of ERTAM protein activity is
lower than seen via a single 1 mg i.p. injection and decays to
background levels rather more rapidly. Nonetheless, we guess that
tamoxifen delivery via the food maintains more consistent ER
fusion activity than can periodic i.p. delivery. Of note, in this study
we used either a mixed 129-C57BL6/J or pure C57BL6/J mouse
strains—although we have not observed any strain-dependent
differences in tamoxifen availability, this remains a possibility that
should be considered in further in vivo studies using switchable ER
fusion proteins.
To investigate the possibility of any adverse impact on general
health through long-term administration of tamoxifen in food,
mice were placed on a tamoxifenized diet for 18 weeks. Over the
ﬁrst week, mice lost an average of 16% body weight, apparently
due to aphagia, but then recovered normal body weight and
thereafter remained healthy, with no abnormalities detectable in
any tissues (Figure 2d). Given the hazards associated with
repeated i.p. injection, our data conﬁrm the administration of
tamoxifen in food as an effective and ethically preferable means of
maintaining ERTAM activity for prolonged periods in vivo.
Figure 2. Restoration and persistence of p53 functionality in p53KI/KI mice after different routes of tamoxifen administration, as assessed
by p53-dependent DNA damage responses in radiosensitive tissues. Tamoxifen was administered to p53KI/KI mice by one of three methods:
(a) 1 mg i.p. injection of tamoxifen in oil; (b) Exposure to tamoxifen diet for 24 h; (c) Exposure to tamoxifen diet for 7 days. Following tamoxifen
exposure, mice were irradiated with 2.5 Gy at the indicated time points post tamoxifen removal and tissues collected 4 h later. Any
p53-dependent radiological response was assayed by quantitating apoptosis in thymus using cleaved caspase-3 (CC3) as an
immunohistochemical marker. Mean and s.e.m. shown, ***Po0.001, **Po0.01, *Po0.05, compared with untreated samples, calculated by
t-test, n⩾ 3. (d) Body weight of mice supplied with tamoxifen-containing diet was assessed weekly (mean and s.e.m. shown; n= 44).
Immunohistochemistry was performed on parafﬁn-embedded 4 μm sections which were deparafﬁnised, treated with citrate buffer for epitope
retrieval and endogenous peroxidises blocked in 3% H2O2. Staining was performed using the Rabbit VECTASTAIN ELITE ABC horseradish
peroxidase kit (Vector Laboratories, Burlingame, CA, USA) following the manufacturer’s protocol. Primary antibody: anti-caspase-3 antibody
(Cell Signalling Technology, Danvers, MA, USA; clone: 5A1E 1:50). Quantiﬁcation was carried out by counting positive stained cells per ﬁeld of
vision, and two representative ﬁelds per mouse per time point were chosen for counting (n⩾ 3 mice). For i.p. injections, tamoxifen base
(T5648, Sigma-Aldrich, St Louis, MO, USA) was dissolved at 100mg/ml in 100% ethanol by heating to 55 °C for 10min, diluted in autoclaved
sunﬂower oil to give a ﬁnal concentration of 10 mg/ml and stored at − 20 °C until use. Before i.p. injection, tamoxifen in oil was warmed to 55 °
C for 10min. Dietary tamoxifen was delivered in Tam400/CreER tamoxifen pellets (400mg tamoxifen citrate per kg supplemented standard
diet Global 2016 pellets), supplied by Harlan Teklad Europe, Boxmeer, The Netherlands. All procedures with animals were carried out in
accordance with Home Ofﬁce UK guidelines.
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